New York, Feb 12, 2026, 15:29 EST — Regular session
Boston Scientific shares edged up roughly 1.2% on Thursday, standing out amid a wider market drop, and last changed hands at $74.38.
The stock held up well even as U.S. indexes dropped over 1%, with investors offloading tech shares and bracing for Friday’s U.S. consumer price index report.
Healthcare showed more resilience. The Health Care Select Sector SPDR Fund gained around 0.7%, even as the SPDR S&P 500 ETF dropped about 1.0%.
Boston Scientific ended Wednesday down 1.1%, trailing several big-name medical device rivals in a day of mixed results.
Volatility continues to focus on the company’s electrophysiology franchise—devices for minimally invasive treatment of heart rhythm issues—following a steep drop last week.
On Feb. 4, the company reported quarterly sales in that segment that missed some analyst forecasts and projected slower growth for 2026, sending its stock down as much as 17%—the biggest one-day drop in over 25 years. Citi analyst Joanne Wuensch said investors’ concerns were “not misplaced.” CEO Michael Mahoney, however, expressed being “really pleased” with the unit’s growth and expects it to outperform the broader electrophysiology market. Reuters
Boston Scientific is forecasting net sales growth between 10.5% and 11.5% for 2026. The company also provided an “organic” growth range, a metric that excludes currency fluctuations and certain acquisition and divestiture impacts. Boston Scientific
A regulatory filing from earlier this month revealed Mahoney exercised options and sold shares through a pre-set Rule 10b5-1 plan.
On Thursday, Stryker shares climbed around 1.3%, while Medtronic gained about 0.7%.
But the setup works both ways. Should Boston Scientific’s upcoming updates reveal a slowdown in the electrophysiology division or its Watchman stroke-prevention device, investors might start doubting the company’s growth prospects again, following last week’s reset.
Traders are eyeing Friday’s CPI report to gauge the next move on rate expectations — and to see if defensive sectors such as healthcare continue drawing money amid a potential deepening of the tech-led selloff.
